However, after stopping treatment, appetite may increase again
In this respect, more research efforts are essential and needed to minimize the risk of pulmonary aspiration and minimize anesthesia risk during sedated medical procedures in patients on GLP-1 RAs
This strategy was tested in the randomized PLATO trial (NCT01995513).[36][Level of evidence B1] Apalutamide, an androgen receptor antagonist, was tested in patients with clinically nonmetastatic, castration-resistant prostate cancer (defined as PSA doubling time 10 months while undergoing androgen deprivation therapy).[37] In the trial, 1,207 men were randomly assigned in a 2:1 ratio to receive either daily apalutamide (240 mg PO) or a placebo
& Plow, E
Take an extended break (4-6 weeks) to allow receptors to reset
The available human data suggest that GLP-1 receptor agonists are safe and generally well tolerated in both acute and chronic settings, which supports continued investigation